Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's another.
https://www.sciencedaily.com/releases/2013/09/130917125022.htm
Red grapes, blueberries may enhance immune function
That has already been known for years. Just replace quadramune with blue berries and its other ingredients that have been studied and scientifically tested for decades. Still nothing new with TSOI. Interesting the prs always come out post dilution.
There are and have been scientific studies for decades. TSOI reports are nothing new.
Same results from past studies. Proof of my assertion are below.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110394/
An immunological perspective for preventing cancer with berries
https://pubmed.ncbi.nlm.nih.gov/29845904/
Dietary supplementation with blueberry partially restores T-cell-mediated function in high-fat-diet-induced obese mice
Erin D Lewis et al. Br J Nutr. 2018 Jun.
Didn't the same results happen when they ate blueberries?
That is wrong. 15 million added were unrestricted. See my previous report showing otc markets share count. Both restricted and unrestricted increased.
Appears a mini pr so the recently given unrestricted shares can be dumped.
Cut and paste. Numbers continue to be atrocious. Compensation for the past 3 months over 60,000 dollars? This is a joke Heddle keeps so when he sells the property he gets every single cent. There is zero equity for shareholder value. Shares are overvalued at .00001
Facts to consider:
90,000 dollars worth of shares being given in just a two week period 7 to 22 Dec. Hundreds of thousands of dollars worth of shares being paid for "consulting services"!
A share structure of over 2.25 billion shares and increasing in the tens of millions every month!
A company with almost no cash, minimal revenue, paying everything with shares while massively diluting shareholder value.
If this company was a private company would you still say it has survived?
Started in 2009
Stopped doing any business related activity in 2013.
Sold land, Selling last piece of property.
90 million dollars in losses.
No revenue. Never a consummated deal.
Never profitable.
Founder charged and fined/banned for 5 years.
Zero employees remain.
That's surviving?
Nice 60 dollar paint job.
How can Nulixo buy a processor when P2O is no longer manufacturing processors? Exactly how can you put any value to the company when the only asset they have is on the market to be sold?
The investor must decide for themselves. Not counting the 10 million shares that were restricted, 15 million unrestricted shares at .006 is 90,000 dollars worth going into someones pocket in just 2 weeks time. 7 to 22 Dec.
Investors deserve answers. Just who is profiting here?
Lets put it in dollars. Looking at just the last three entries.
Aug 26 $50,000
Sep 23 $8,500
Sep 29 $18,750
Total consulting services in one month. $77,250 worth of shares. Someone is getting rich,
And to know this continues every week/month. Just wait for the annual report.
On August 26, 2020, we issued 10,000,000 shares of common stock, valued at $0.005 per share, for consulting services.
On September 23, 2020, we issued 1,000,000 shares of common stock, valued at $0.0085 per share, for consulting services.
On September 29, 2020, we issued 2,500,000 shares of common stock, valued at $0.0075 per share, for consulting services.
13 percent drop, that's dilution for you. CEO posted the below, still doesn't explain who received a majority of those shares, "consulting services"??? and still waiting on the Decembers dilution answer as that was the basis for the question. 15 million in unrestricted shares from 7 Dec to 22 Dec as listed on OTCmarkets.com
PART II - OTHER INFORMATION
Item 1A. Risk Factors
No material changes to risk factors have occurred as previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on May 21, 2020.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On March 2, 2020 we issued 8,333,333 shares of common stock for the partial conversion of $10,000 for a convertible note dated August 28, 2019.
On March 12, 2020 we issued 11,764,706 shares of common stock for the partial conversion of $10,000 for convertible note dated August 28, 2019.
On March 26, 2020 we issued 21,818,182 shares of common stock for the partial conversion of $12,000 for convertible note dated August 28, 2019.
On June 4, 2020, we issued 24,733,333 shares of common stock for the complete conversion of $29,680 for convertible note dated October 30, 2019.
On June 4, 2020, we issued 5,000,000 shares of common stock, valued at $0.0023 per share, for consulting services.
On June 4, 2020 we issued 70,000,000 shares of common stock, valued at $0.023 each to three officers and one director of the Company under a Restricted Stock Award.
On June 8, 2020, we issued 10,000,000 shares of common stock, valued at $0.0033 per share, for consulting services.
On June 9, 2020, we issued 18,292,818 shares of common stock for the complete conversion of $60,000 for convertible note dated June 9, 2020.
On June 11, 2020 we issued 40,000,000 shares of common stock, valued at $0.0046 each to three officers and one director of the Company under a Restricted Stock Award.
On June 15, 2020 we issued 3,000,000 shares of common stock, valued at $0.0017 each to one officer and one director of the Company under a Restricted Stock Award.
On June 15, 2020, we issued 10,000,000 shares of common stock, valued at $0.0023 per share, to the medical officer for consulting services.
On June 16, 2020, we issued 33,566,667 shares of common stock for the complete conversion of $40,280 for convertible note dated December 12, 2019.
On June 22, 2020, we issued 8,000,000 shares of common stock, valued at $0.0029 per share, for a donation in Triton Funds LP pursuant to the Donation Agreement (“DA”) and Registration Rights Agreement (“RRA”) dated January 24, 2020.
On June 25, 2020, we issued 10,000,000 shares of common stock, valued at $0.0083 per share, to the medical officer for consulting services.
On July 17, 2020 we issued 7,500,000 shares of common stock, valued at $0.0064 each to two officers, and one director of the Company under a Restricted Stock Award.
29
On July 17, 2020, we issued 2,000,000 shares of common stock, valued at $0.0064 per share, for consulting services.
On July 31, 2020 we issued 12,000,000 shares of common stock, valued at .0077 each to three officers, and one director of the Company under a Restricted Stock Award.
On August 4, 2020, we issued 8,969,230 shares of common stock for the complete conversion of $34,980 for convertible note dated February 4, 2020.
On August 26, 2020, we issued 10,000,000 shares of common stock, valued at $0.005 per share, for consulting services.
On September 23, 2020, we issued 1,000,000 shares of common stock, valued at $0.0085 per share, for consulting services.
On September 29, 2020, we issued 2,500,000 shares of common stock, valued at $0.0075 per share, for consulting services.
How can heddle sell a processor when the only one he has is broken and they no longer manufacture processors?
With total denial that the company is dead. Freud would be very busy analyzing this phenomenom called batshit crazy.
One call to Heddle confirmed the company is dead and zero activity expected outside of selling the company's last remaining property. Nulixo well aware yet they refuse to update their website or the public.
Whats worse is the fraud perpetrated by the conspiracy lies. All the while reality is so easily ignored.
What does any of that have to do with Heddle and P2O? Company is shuttered as per Heddle. Company no longer manufacturing processors as per Heddle. Not having processors nullifies nulixo's deal to buy P2O processors. The worthless stock trade analysis only shows that there are gullible people willing to buy shares of a company that has not been operational for over 7 years. It shows more of ignorance than conspiracy.
should be a good week!
Things are looking up. 2021 should be a much better year. At least 15 dollars per share by December 21'.
Sad isn't it that the CEO is such that he has childish tantrums on his forum. Calling people childish names and ignoring the important items addressed here. He refuses to say who is getting the unrestricted shares. Instead he says every company continually dilutes its stock. The CEO must monitor this board every second, now what type of a CEO monitors a stock message board? hmmmmmmmmmmm. Exactly.
What news are you looking for? They no longer manufacture processors. So they have none to sell. They have been shut down since 2013. That's almost 8 years ago. So no longer making processors exactly what value do you put on the magic catalyst and recipe? If one believes thats all they have what is it worth? Answer: Zilch
95 percent (depending the source) of patents never make money. applications or patent pending mean nothing. revenue, Share structure, and market cap matters. That's it. Revenue non existent, no govt money, Shares continually being used. over 25 million shares added between 7 and 22 December. 15 million were unrestricted. So who is being "paid" these shares?
https://www.allbusiness.com/97-percent-of-all-patents-never-make-any-money-15258080-1.html
Yet the massive dilution continues as there is no cash. Everything being paid in shares.
With the continued constant dilution? Not quite. With over 2,225,000,000 shares? Thats over 2.2 billion, only a reverse split will bring legitimacy to the share price. But ceo doesn't care. Dilution to continue. Will be closer to 3 billion by June. 3.5 billion by end of 2021.
More dilution with latest update. Both restricted and unrestricted. Ouch. So just who is being given these unrestricted shares?
Outstanding Shares
2,225,741,391
12/22/2020
Restricted
1,429,353,707
12/22/2020
Unrestricted
796,387,684
12/22/2020
Previous, as posted
Outstanding Shares
2,200,024,150
12/07/2020
Restricted
1,419,353,707
12/07/2020
Unrestricted
780,670,443
12/07/2020
They have zero P2O processors. P2O does not make processors. P2O has no money to buy processors to resell. Nulixo has no money to buy red wave equipment or processors. They are a pipe dream if not fraudulant.
That's funny. Nulixo is a company on paper only.
And his latest:
I want to offer my personal thanks for the extremely valuable contributions made by our employees, management, Board of Directors, and investors. I also look forward to seeing you and sharing further developments at our next annual stockholders meeting, being planned for early next year. Formal notice and other details of the meeting will be presented in our proxy statement, which will be made available to our stockholders and filed with the Securities and Exchange Commission. Thank you for your continued support.
Oct 2017
And this one:
I want to offer my personal thanks for the extremely valuable contributions made by our employees, management, Board of Directors, and investors. I also look forward to seeing you and sharing further developments at our 2017 annual stockholders meeting, planned for late this year. Formal notice and other details of the meeting will be presented in our proxy statement, which will be made available to our stockholders and filed with the Securities and Exchange Commission. Thank you for your continued support.
all one has to do is go back and read Heddle's letters to share holders to know they've been scammed. Like this one:
I also look forward to seeing you and sharing with you further developments at our 2015 annual stockholders meeting, which
is being planned for late this summer. Formal notice and other details of the meeting will be presented in our proxy statement that will be made available to our stockholders and filed with
the Securities and Exchange Commission.
Sincerely,
Richard Heddle, President and CEO
Sad isn't it? They link the P2O website which has not been updated since December 29, 2017. Filled with untruths and scam language. P2O no longer makes their own processor. So who does?
The scam language? how about this: "fuel which does not require further refining, directly from unwashed, unsorted waste plastics." and this
Plastic2Oil® has been issued an exemption from Air Permitting in the state where the first site will be located for the agreement with Rock-Tenn Company ("RockTenn").
not to mention every single pr listed has been a lie. Every one.
https://www.plastic2oil.com/site/news-releases
I'll revisit June 2021. Not going to worry about this crap now. May all have a very Merry Christmas and a very Happy and profitable New Year!
Lucky for those that bought at 7.
As I stated before, this company is not relying on galidesivir nor is the pps. Revenue created as we speak by berotralstat aka Orladeyo. Other updates show we are at the beginning of a great expansion regardless of gal.
I agree also. A perfect description.
2021 going to be a great year, no doubt.
Yet still a very good drug in their arsenal. Gal was always the icing not the cake. With Orledeyo now marketed, the factor D and Galidesivir safe and positive antiviral aspects in other diseases, biocryst is set for the future. I think the vaccinations now out may be the reason for naiad's/biocrysts decision on Covid 19. And yet study of the drug continues. Do not underestimate this company.
Part 1 Results
The primary objective of part 1 of the dose-ranging study was to evaluate the safety of galidesivir. No safety signals were identified, and all three dose levels were equally safe.
Secondary objectives were to evaluate the effect of galidesivir on the clinical course of COVID-19 and on SARS-CoV-2 infection in the respiratory tract.
Galidesivir treatment was associated with a more rapid decline in viral RNA levels in the respiratory tract in an apparent dose-dependent manner.
A separate study of galidesivir in a COVID-19 animal model showed that early administration of galidesivir reduced SARS-CoV-2 viral burden in lung tissue (1.4-1.6 log lower tissue viral burden) and was associated with a significant reduction in damage to lung tissue, compared to vehicle control treated animals. These results suggest that early antiviral treatment of SARS-CoV-2 infection may protect against developing severe COVID-19 lung disease.
Yup, P2O's replacement?